Last reviewed 2026-06-02 · How we verify

Postafen (MEDRYLAMINE)

Phase 2 active Small molecule ✓ Verified Jun 2026

Postafen (generic name: MEDRYLAMINE) is a drug. It is currently in Phase 2 development.

Postafen works by binding to and modulating the activity of specific proteins or receptors in the body.

Postafen is a small molecule medication. It is also known as Medrilamina or Medrylamine.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	MEDRYLAMINE
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Think of it like a key fitting into a lock. Postafen is like the key, and the lock is a specific protein or receptor in the body. When the key fits into the lock, it can either turn the lock (activating the protein) or block the lock (inhibiting the protein), which can help to treat a particular disease or condition.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Postafen CI brief — competitive landscape report
Postafen updates RSS · CI watch RSS

Frequently asked questions about Postafen

What is Postafen?

Postafen (MEDRYLAMINE) is a Small molecule drug.

How does Postafen work?

Postafen works by binding to and modulating the activity of specific proteins or receptors in the body.

What is the generic name of Postafen?

MEDRYLAMINE is the generic (nonproprietary) name of Postafen.

What development phase is Postafen in?

Postafen is in Phase 2.

Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing